What Is Tavapadon? Understanding This New Approach for Managing Parkinson’s Motor Symptoms

medication developed as a selective partial agonist at the D1 and D5 dopamine receptors. Unlike many existing dopamine agonists that primarily activate D2 and D3 receptors, tavapadon targets the D1/D5 family, which plays a key role in the brain’s “direct pathway” for initiating and smoothing movement.

Think of it like this: the brain has multiple dopamine “switches.” Traditional agonists press several at once, which can overstimulate certain areas and contribute to side effects. Tavapadon aims to activate specific switches more gently and selectively as a partial agonist, meaning it